TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS

骨髓增生异常和骨髓纤维化的移植

基本信息

项目摘要

Allogeneic stem cell transplantation is the only known curative treatment for myelodysplasia (MDS). The disease is heterogeneous and our previous experience suggests that it is possible to adjust transplant approaches to specific clinical situations. In patients with less advanced MDS (that is, MDS without excess blasts) the risk of relapse after conventional transplant preparative regimens of cyclophosphamide (CY) and total body irradiation (TBI) or busulfan (BU) and CT is less than 5% and the major cause of failure is treatment-related fatality. In such patients undergoing human leukocyte antigen (HLA)-identical related donor transplantation, a regimen of CY-TBI with liver and lung shielding will be evaluated to estimate whether this approach can reduce treatment-related fatality without an increase in relapse. In patients with less advanced MDS undergoing unrelated donor transplantation, to retain sufficient immunosuppression while reducing toxicity of the cytotoxic component, a regimen of BU-CY with pharmacokinetic targeting of BU levels will be evaluated. In patients with advanced MDS (that is, MDS with excess blasts or chronic myelomonocytic leukemia) conventional preparative regimens result in high relapse rates and intensified preparative regimens such as BU-CY-TBI reduce relapse but increase toxicity. In such patients under age 56, we will test whether a regimen of BU-TBI retains the superior anti- tumor effect of BU-CY-TBI, but reduces toxicity. In older patients with advanced MDS, fatal toxicity of the transplant procedure is high and therefor the regimen of BU-CY with pharmacokinetic targeting of BU levels will be tested. Myelofibrosis is a related clonal myeloid disorder in which progressive fibrosis results in life-threatening cytopenias and organomegaly. Stem cell transplantation offers curative treatment to such patients but has rarely been attempted. The feasibility of allogeneic transplantation in patients with underlying myeloproliferative disorders associated with marrow fibrosis will be tested.
同种异体干细胞移植是唯一已知的治疗方法

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FREDERICK APPLEBAUM其他文献

FREDERICK APPLEBAUM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FREDERICK APPLEBAUM', 18)}}的其他基金

TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
  • 批准号:
    6338859
  • 财政年份:
    2000
  • 资助金额:
    $ 16.81万
  • 项目类别:
TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
  • 批准号:
    6202257
  • 财政年份:
    1999
  • 资助金额:
    $ 16.81万
  • 项目类别:
TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
  • 批准号:
    6109817
  • 财政年份:
    1998
  • 资助金额:
    $ 16.81万
  • 项目类别:
MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA
淋巴瘤患者的骨髓移植
  • 批准号:
    3793583
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE NONLYMPHOBLATIC LEUKEMI
急性非淋巴细胞白血病患者的自体骨髓移植
  • 批准号:
    3817222
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA
淋巴瘤患者的骨髓移植
  • 批准号:
    5206899
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA
淋巴瘤患者的骨髓移植
  • 批准号:
    3805845
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA
淋巴瘤患者的骨髓移植
  • 批准号:
    3771402
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH MALIGNANT LYMPHOMA
恶性淋巴瘤患者的自体骨髓移植
  • 批准号:
    3807909
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH MALIGNANT LYMPHOMA
恶性淋巴瘤患者的自体骨髓移植
  • 批准号:
    3817223
  • 财政年份:
  • 资助金额:
    $ 16.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了